Dive Brief:
- Senseonics has partnered with Sequel Med Tech to use its one-year continuous glucose monitor implant in an automated insulin delivery system, the companies said Tuesday.
- The partnership extends the compatibility of Sequel’s Twiist system to allow people with Type 1 diabetes to use Senseonics’ Eversense 365 CGM to track blood glucose and inform insulin dosing.
- Senseonics and Sequel are planning to launch the system in the third quarter. BTIG analysts said in a note to investors that they expect the collaboration to have limited commercial impact on Senseonics in “the first few quarters.”
Dive Insight:
The Food and Drug Administration cleared Eversense 365 as an integrated CGM in September. As well as extending the lifespan of the implant and reducing the need for fingerstick calibration, the clearance put Senseonics in a position to integrate the CGM with insulin pumps to create AID systems.
Sequel is the first insulin pump firm to work with Senseonics. Deka Research & Development, Sequel’s partner, received 510(k) clearance for Twiist in March 2024. The system uses an AID app developed by the nonprofit Tidepool. Sequel partnered with Abbott to integrate Twiist with the Freestyle Libre 3 Plus Sensor in March 2025. Twiist is set to launch commercially in the U.S. in the second quarter.
BTIG analysts said they “expect limited commercial impact for [Senseonics] over the first few quarters since Twiist is just being launched this quarter.” The analysts called the deal “the first step in enhancing the interoperability of Eversense beyond a standalone CGM.”
Senseonics has discussed its work to enhance the interoperability of Eversense 365 on recent calls with investors.
At a TD Cowen event in March, Mukul Jain, chief operating officer at Senseonics, said the team had “passed prototyping in a couple of instances” with potential pump partners and hoped to be able to talk publicly about the integrations in the coming quarters.
Jain said “you have to be compatible with everyone” because patients may change their CGM or pump. Asked if pump partnerships will accelerate growth, Jain said “it will certainly be a validation of the product” but added that “the proportion of people who are managing their diabetes with multiple daily injections is very high.”
Senseonics can already serve patients who manage diabetes with insulin injections.
